Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants

Science Translational Medicine

Volumn 2, Issue 38, 2010, Pages

  Politis, Marios ^a   Wu, Kit ^a   Loane, Clare ^a   Quinn, Niall P ^b   Brooks, David J ^a   Rehncrona, Stig ^c   Bjorklund, Anders ^d   Lindvall, Olle ^d,e   Piccini, Paola ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d LUND UNIVERSITY   (Sweden)

^e LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

6 FLUORODOPA F 18; AMANTADINE; APOMORPHINE; BROMOCRIPTINE; BUSPIRONE; DOPAMINE; ENTACAPONE; LEVODOPA; METHAMPHETAMINE; PLACEBO; PRAMIPEXOLE; RACLOPRIDE C 11; ROPINIROLE; ROTIGOTINE; TRIHEXYPHENIDYL; SEROTONIN; SEROTONIN AGONIST;

ABSENCE OF SIDE EFFECTS; AGED; ARM MOVEMENT; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE SEVERITY; DOPAMINE BLOOD LEVEL; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DYSKINESIA; FACIAL INVOLUNTARY MOVEMENT; FEMALE; GRAFT INDUCED DYSKINESIA; HUMAN; HUMAN TISSUE; INNERVATION; INTRASTRIATAL FETAL VENTRAL MESENCEPHALIC TISSUE TRANSPLANTATION; INVOLUNTARY MOVEMENT; LEG MOVEMENT; MALE; MESENCEPHALON; MOTOR PERFORMANCE; NERVE TRANSPLANTATION; ORAL INVOLUNTARY MOVEMENT; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; REPEATED DRUG DOSE; SEROTONINERGIC HYPERINNERVATION; SEROTONINERGIC NERVE CELL; TREATMENT OUTCOME; TRUNK; UNIFIED PARKINSON DISEASE RATING SCALE; VENTRAL MESENCEPHALON; FETUS; HISTOLOGY; METABOLISM; MIDDLE AGED; NEOSTRIATUM; NERVE CELL; TRANSPLANTATION;

AGED; DOPAMINE; DYSKINESIAS; FEMALE; FETUS; HUMANS; MALE; MESENCEPHALON; MIDDLE AGED; NEOSTRIATUM; NEURONS; PARKINSON DISEASE; SEROTONIN; SEROTONIN RECEPTOR AGONISTS; TRANSPLANTS;

EID: 77955617871     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3000976     Document Type: Article

References (39)

1. O. Lindvall, A. Björklund, Cell therapy in Parkinson's disease. NeuroRx 1, 382-393 (2004).
2. C. R. Freed, P. E. Greene, R. E. Breeze, W. Y. Tsai, W. DuMouchel, R. Kao, S. Dillon, H. Winfield, S. Culver, J. Q. Trojanowski, D. Eidelberg, S. Fahn, Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med. 344, 710-719 (2001).
3. P. Hagell, P. Piccini, A. Björklund, P. Brundin, S. Rehncrona, H. Widner, L. Crabb, N. Pavese, W. H. Oertel, N. Quinn, D. J. Brooks, O. Lindvall, Dyskinesias following neural transplantation in Parkinson's disease. Nat. Neurosci. 5, 627-628 (2002).
4. C. W. Olanow, C. G. Goetz, J. H. Kordower, A. J. Stoessl, V. Sossi, M. F. Brin, K. M. Shannon, G. M. Nauert, D. P. Perl, J. Godbold, T. B. Freeman, A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann. Neurol. 54, 403-414 (2003).
5. C. W. Olanow, J. M. Gracies, C. G. Goetz, A. J. Stoessl, T. Freeman, J. H. Kordower, J. Godbold, J. A. Obeso, Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: A double blind video-based analysis. Mov. Disord. 24, 336-343 (2009).
6. P. Piccini, N. Pavese, P. Hagell, J. Reimer, A. Björklund, W. H. Oertel, N. P. Quinn, D. J. Brooks, O. Lindvall, Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain 128, 2977-2986 (2005).
7. M. Carta, T. Carlsson, D. Kirik, A. Björklund, Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 130, 1819-1833 (2007).
8. I. Mendez, A. Viñuela, A. Astradsson, K. Mukhida, P. Hallett, H. Robertson, T. Tierney, R. Holness, A. Dagher, J. Q. Trojanowski, O. Isacson, Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat. Med. 14, 507-509 (2008).
9. G. K. Wenning, P. Odin, P. Morrish, S. Rehncrona, H. Widner, P. Brundin, J. C. Rothwell, R. Brown, B. Gustavii, P. Hagell, M. Jahanshahi, G. Sawle, A. Björklund, D. J. Brooks, C. D. Marsden, N. P. Quinn, O. Lindvall, Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann. Neurol. 42, 95-107 (1997).
10. P. Hagell, A. Schrag, P. Piccini, M. Jahanshahi, R. Brown, S. Rehncrona, H. Widner, P. Brundin, J. C. Rothwell, P. Odin, G. K. Wenning, P. Morrish, B. Gustavii, A. Björklund, D. J. Brooks, C. D. Marsden, N. P. Quinn, O. Lindvall, Sequential bilateral transplantation in Parkinson's disease: Effects of the second graft. Brain 122, 1121-1132 (1999).
11. P. Brundin, O. Pogarell, P. Hagell, P. Piccini, H. Widner, A. Schrag, A. Kupsch, L. Crabb, P. Odin, B. Gustavii, A. Björklund, D. J. Brooks, C. D. Marsden, W. H. Oertel, N. P. Quinn, S. Rehncrona, O. Lindvall, Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain 123, 1380-1390 (2000).
12. T. Carlsson, M. Carta, C. Winkler, A. Björklund, D. Kirik, Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease. J. Neurosci. 27, 8011-8022 (2007).
13. T. Carlsson, M. Carta, A. Muñoz, B. Mattsson, C. Winkler, D. Kirik, A. Björklund, Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. Brain 132, 319-335 (2009).
14. C. J. Schmidt, W. Lovenberg, In vitro demonstration of dopamine uptake by neostriatal serotonergic neurons of the rat. Neurosci. Lett. 59, 9-14 (1985).
15. S. N. Saldaña, E. L. Barker, Temperature and 3,4- methylenedioxymethamphetamine alter human serotonin transporter-mediated dopamine uptake. Neurosci. Lett. 354, 209-212 (2004).
16. K. Kannari, H. Shen, A. Arai, M. Tomiyama, M. Baba, Reuptake of L-DOPA-derived extracellular dopamine in the striatum with dopaminergic denervation via serotonin transporters. Neurosci. Lett. 402, 62-65 (2006).
17. 1A agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy. Pharmacol. Biochem. Behav. 87, 306-314 (2007).
18. V. Cochen, M. J. Ribeiro, J. P. Nguyen, J. M. Gurruchaga, G. Villafane, C. Loc'h, G. Defer, Y. Samson, M. Peschanski, P. Hantraye, P. Cesaro, P. Remy, Transplantation in Parkinson's disease: PET changes correlate with the amount of grafted tissue. Mov. Disord. 18, 928-932 (2003).
19. J. H. Kordower, Y. Chu, R. A. Hauser, T. B. Freeman, C. W. Olanow, Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat. Med. 14, 504-506 (2008).
20. J. H. Kordower, Y. Chu, R. A. Hauser, C. W. Olanow, T. B. Freeman, Transplanted dopaminergic neurons develop PD pathologic changes: A second case report. Mov. Disord. 23, 2303-2306 (2008).
21. 3H]dopamine via reversal of the dopamine transporter in rat striatum and nucleus accumbens: A comparison with release elicited by potassium, N-methyl-D-aspartic acid, glutamic acid and D-amphetamine. J. Pharmacol. Exp. Ther. 262, 356-364 (1992).
22. S. K. Yeghiayan, A. E. Kelley, Serotonergic stimulation of the ventrolateral striatum induces orofacial stereotypy. Pharmacol. Biochem. Behav. 52, 493-501 (1995).
23. S. K. Yeghiayan, A. E. Kelley, N. S. Kula, A. Campbell, R. J. Baldessarini, Role of dopamine in behavioral effects of serotonin microinjected into rat striatum. Pharmacol. Biochem. Behav. 56, 251-259 (1997).
24. H. Braak, K. Del Tredici, Assessing fetal nerve cell grafts in Parkinson's disease. Nat. Med. 14, 483-485 (2008).
25. J. W. Fawcett, R. A. Barker, S. B. Dunnett, Dopaminergic neuronal survival and the effects of bFGF in explant, three dimensional and monolayer cultures of embryonic rat ventral mesencephalon. Exp. Brain Res. 106, 275-282 (1995).
26. A. J. Hughes, S. E. Daniel, L. Kilford, A. J. Lees, Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55, 181-184 (1992).
27. O. Lindvall, H. Widner, S. Rehncrona, P. Brundin, P. Odin, B. Gustavii, R. Frackowiak, K. L. Leenders, G. Sawle, J. C. Rothwell, A. Björklund, C. D. Marsden, Transplantation of fetal dopamine neurons in Parkinson's disease: One-year clinical and neurophysiological observations in two patients with putaminal implants. Ann. Neurol. 31, 155-165 (1992).
28. O. Lindvall, S. Rehncrona, P. Brundin, B. Gustavii, B. Astedt, H. Widner, T. Lindholm, A. Björklund, K. L. Leenders, J. C. Rothwell, R. Frackowiak, C. D. Marsden, B. Johnels, G. Steg, R. Freedman, B. J. Hoffer, Å. Seiger, M. Bygdeman, I. Strömberg, L. Olson, Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up. Arch. Neurol. 46, 615-631 (1989).
29. I. Mahmood, C. Sahajwalla, Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. Clin. Pharmacokinet. 36, 277-287 (1999).
30. G. Brix, J. Zaers, L. E. Adam, M. E. Bellemann, H. Ostertag, H. Trojan, U. Haberkorn, J. Doll, F. Oberdorfer, W. J. Lorenz, Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. J. Nucl. Med. 38, 1614-1623 (1997).
31. T. J. Spinks, T. Jones, P. M. Bloomfield, D. L. Bailey, M. Miller, D. Hogg, W. F. Jones, K. Vaigneur, J. Reed, J. Young, D. Newport, C. Moyers, M. E. Casey, R. Nutt, Physical characteristics of the ECAT EXACT3D positron tomograph. Phys. Med. Biol. 45, 2601-2618 (2000).
32. S. J. Kish, Y. Furukawa, L. J. Chang, J. Tong, N. Ginovart, A. Wilson, S. Houle, J. H. Meyer, Regional distribution of serotonin transporter protein in postmortem human brain: Is the cerebellum a SERT-free brain region? Nucl. Med. Biol. 32, 123-128 (2005).
33. A. J. Montgomery, K. Thielemans, M. A. Mehta, F. Turkheimer, S. Mustafovic, P. M. Grasby, Correction of head movement on PET studies: Comparison of methods. J. Nucl. Med. 47, 1936-1944 (2006).
34. H. M. Duvernoy, The Human Brain: Surface, Blood Supply, and Three-Dimensional Sectional Anatomy (Springer-Verlag Wien, New York, 1999).
35. J. Logan, J. S. Fowler, N. D. Volkow, G. J. Wang, Y. S. Ding, D. L. Alexoff, Distribution volume ratios without blood sampling from graphical analysis of PET data. J. Cereb. Blood Flow Metab. 16, 834-840 (1996).
36. N. Ginovart, A. A. Wilson, J. H. Meyer, D. Hussey, S. Houle, Positron emission tomography quantification of [11C]-DASB binding to the human serotonin transporter: Modeling strategies. J. Cereb. Blood Flow Metab. 21, 1342-1353 (2001).
37. R. B. Innis, V. J. Cunningham, J. Delforge, M. Fujita, A. Gjedde, R. N. Gunn, J. Holden, S. Houle, S. C. Huang, M. Ichise, H. Iida, H. Ito, Y. Kimura, R. A. Koeppe, G. M. Knudsen, J. Knuuti, A. A. Lammertsma, M. Laruelle, J. Logan, R. P. Maguire, M. A. Mintun, E. D. Morris, R. Parsey, J. C. Price, M. Slifstein, V. Sossi, T. Suhara, J. R. Votaw, D. F. Wong, R. E. Carson, Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metab. 27, 1533-1539 (2007).
38. 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann. Neurol. 28, 547-555 (1990).
39. R. N. Gunn, A. A. Lammertsma, S. P. Hume, V. J. Cunningham, Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 6, 279-287 (1997).